1-8 of 8
Ulrich Steidl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

Available to Purchase
Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, Kith Pradhan, Mimi Kim, Ioannis Mantzaris, R. Alejandro Sica, Nishi Shah, Mendel Goldfinger, Noah Kornblum, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Britta Will, Aditi Shastri, Amit Verma
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 60–66.
https://doi.org/10.1158/1078-0432.CCR-22-1457
Published: 04 January 2023
View articletitled, Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial
Open the PDF for Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Open Access
Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 429.
https://doi.org/10.1158/1078-0432.CCR-21-4241
Published: 15 January 2022
View articletitled, Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Open the PDF for Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 in another window
Journal Articles

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Open Access
Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5236–5247.
https://doi.org/10.1158/1078-0432.CCR-21-0715
Published: 01 October 2021
View articletitled, Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Open the PDF for Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 in another window
Includes: Supplementary data
Journal Articles

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

Free
Valeria Santini, David Valcárcel, Uwe Platzbecker, Rami S. Komrokji, Ann L. Cleverly, Michael M. Lahn, Jan Janssen, Yumin Zhao, Alan Chiang, Aristoteles Giagounidis, Susan C. Guba, Ivelina Gueorguieva, Allicia C. Girvan, Mariana da Silva Ferreira, Tushar D. Bhagat, Kith Pradhan, Ulrich Steidl, Ashwin Sridharan, Britta Will, Amit Verma
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (23): 6976–6985.
https://doi.org/10.1158/1078-0432.CCR-19-1338
Published: 02 December 2019
View articletitled, Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
Open the PDF for Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes in another window
Includes: Supplementary data
Journal Articles

Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?

Free
Richard T. Piszczatowski, Ulrich Steidl
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4868–4870.
https://doi.org/10.1158/1078-0432.CCR-19-1481
Published: 15 August 2019
View articletitled, Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?
Open the PDF for Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy? in another window
Journal Articles

PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma

Free
Elaine Y. Chung, Yun Mai, Urvi A. Shah, Yongqiang Wei, Elise Ishida, Keisuke Kataoka, Xiaoxin Ren, Kith Pradhan, Boris Bartholdy, Xiaolei Wei, Yiyu Zou, Jinghang Zhang, Seishi Ogawa, Ulrich Steidl, Xingxing Zang, Amit Verma, Murali Janakiram, B. Hilda Ye
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3589–3601.
https://doi.org/10.1158/1078-0432.CCR-18-3033
Published: 14 June 2019
View articletitled, PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma
Open the PDF for PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract IA01: Mechanisms of formation and progression of preleukemic stem cells

Free
Ulrich Steidl
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): IA01.
https://doi.org/10.1158/1557-3265.HEMMAL17-IA01
Published: 14 December 2017
View articletitled, Abstract IA01: Mechanisms of formation and progression of preleukemic stem cells
Journal Articles

Prognostic Relevance of Fragile Histidine Triad Protein Expression in Patients with Small Cell Lung Cancer

Free
Ulrich-Peter Rohr, Nina Rehfeld, Helene Geddert, Lucy Pflugfelder, Ingmar Bruns, Judith Neukirch, Astrid Rohrbeck, Hans J. Grote, Ulrich Steidl, Roland Fenk, Bertram Opalka, Helmut E. Gabbert, Ralf Kronenwett, Rainer Haas
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 180–185.
https://doi.org/10.1158/1078-0432.180.11.1
Published: 21 January 2005
View articletitled, Prognostic Relevance of Fragile Histidine Triad Protein Expression in Patients with Small Cell Lung Cancer
Open the PDF for Prognostic Relevance of Fragile Histidine Triad Protein Expression in Patients with Small Cell Lung Cancer in another window